These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28271944)

  • 1. An Assessment of Intralesional Epidermal Growth Factor for Treating Diabetic Foot Wounds
    Ertugrul BM; Lipsky BA; Guvenc U;
    J Am Podiatr Med Assoc; 2017 Jan; 107(1):17-29. PubMed ID: 28271944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intralesional application of epidermal growth factor in limb-threatening ischemic diabetic foot ulcers.
    Aktaş Ş; Baktıroğlu S; Demir L; Kılıçoğlu Ö; Topalan M; Güven E; Mirasoğlu B; Yanar F
    Acta Orthop Traumatol Turc; 2016; 50(3):277-83. PubMed ID: 27130382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of intralesional recombinant human epidermal growth factor in chronic diabetic foot ulcers.
    Dumantepe M; Fazliogullari O; Seren M; Uyar I; Basar F
    Growth Factors; 2015 Apr; 33(2):128-32. PubMed ID: 25856197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intralesional Epidermal Growth Factor for Diabetic Foot Ulcers.
    Ilkeli E; Goktas Demircan FB; Duzgun AC; Arabaci H; Uysal A; Kanko M
    J Coll Physicians Surg Pak; 2022 Mar; 32(3):278-282. PubMed ID: 35148575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intralesional epidermal growth factor for diabetic foot wounds: the first cases in Turkey.
    Ertugrul BM; Buke C; Ersoy OS; Ay B; Demirez DS; Savk O
    Diabet Foot Ankle; 2015; 6():28419. PubMed ID: 26268583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Long-Term Outcomes Following the Application of Intralesional Epidermal Growth Factor in Patients With Diabetic Foot Ulcers.
    Kahraman M; Misir A; Kizkapan TB; Ozcamdalli M; Uzun E; Mutlu M
    J Foot Ankle Surg; 2019 Mar; 58(2):282-287. PubMed ID: 30612874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds.
    Acosta JB; Savigne W; Valdez C; Franco N; Alba JS; del Rio A; López-Saura P; Guillén G; Lopez E; Herrera L; Férnandez-Montequín J
    Int Wound J; 2006 Sep; 3(3):232-9. PubMed ID: 16984579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers.
    Yera-Alos IB; Alonso-Carbonell L; Valenzuela-Silva CM; Tuero-Iglesias AD; Moreira-Martínez M; Marrero-Rodríguez I; López-Mola E; López-Saura PA
    BMC Pharmacol Toxicol; 2013 Sep; 14():44. PubMed ID: 24004460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of intralesional recombinant human epidermal growth factor in diabetic foot ulcers in Mexican patients: a randomized double-blinded controlled trial.
    Gomez-Villa R; Aguilar-Rebolledo F; Lozano-Platonoff A; Teran-Soto JM; Fabian-Victoriano MR; Kresch-Tronik NS; Garrido-Espíndola X; Garcia-Solis A; Bondani-Guasti A; Bierzwinsky-Sneider G; Contreras-Ruiz J
    Wound Repair Regen; 2014; 22(4):497-503. PubMed ID: 25041620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intralesional epidermal growth factor therapy in recalcitrant diabetic foot ulcers.
    Özker E
    J Wound Care; 2023 Apr; 32(Sup4):S14-S21. PubMed ID: 37029977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study.
    Fernández-Montequín JI; Valenzuela-Silva CM; Díaz OG; Savigne W; Sancho-Soutelo N; Rivero-Fernández F; Sánchez-Penton P; Morejón-Vega L; Artaza-Sanz H; García-Herrera A; González-Benavides C; Hernández-Cañete CM; Vázquez-Proenza A; Berlanga-Acosta J; López-Saura PA;
    Int Wound J; 2009 Dec; 6(6):432-43. PubMed ID: 20051095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure.
    Fernández-Montequín JI; Betancourt BY; Leyva-Gonzalez G; Mola EL; Galán-Naranjo K; Ramírez-Navas M; Bermúdez-Rojas S; Rosales F; García-Iglesias E; Berlanga-Acosta J; Silva-Rodriguez R; Garcia-Siverio M; Martinez LH
    Int Wound J; 2009 Feb; 6(1):67-72. PubMed ID: 19291119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intralesional epidermal growth factor therapy fordiabetic foot ulcers: an evaluation of 15 cases.
    Işıkgöz Taşbakan M; Yıldırım Şimşir I; Mermer S; Uysal S; Öztürk M; Çetinkalp Ş
    Turk J Med Sci; 2017 Nov; 47(5):1500-1504. PubMed ID: 29151322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic translation of locally infiltrated epidermal growth factor in diabetic lower extremity wounds.
    García-Ojalvo A; Berlanga Acosta J; Figueroa-Martínez A; Béquet-Romero M; Mendoza-Marí Y; Fernández-Mayola M; Fabelo-Martínez A; Guillén-Nieto G
    Int Wound J; 2019 Dec; 16(6):1294-1303. PubMed ID: 31429187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation.
    Fernández-Montequín JI; Infante-Cristiá E; Valenzuela-Silva C; Franco-Pérez N; Savigne-Gutierrez W; Artaza-Sanz H; Morejón-Vega L; González-Benavides C; Eliseo-Musenden O; García-Iglesias E; Berlanga-Acosta J; Silva-Rodríguez R; Betancourt BY; López-Saura PA;
    Int Wound J; 2007 Dec; 4(4):333-43. PubMed ID: 17953679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can Intralesional Epidermal Growth Factor Reduce Skin Graft Applications in Patients with Diabetic Foot Ulcer?
    Colak B; Yormaz S; Ece I; Sahin M
    J Am Podiatr Med Assoc; 2021 Sep; 111(5):. PubMed ID: 34861684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Efficiency of Epidermal Growth Factor and Negative Pressure Wound Therapy in Diabetic Foot Patients.
    Yastı AÇ; Karaca T; Kendirci M; Akgün AE; Şahiner İT; Akın M
    Int J Low Extrem Wounds; 2023 Mar; 22(1):93-102. PubMed ID: 36069057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intralesional epidermal growth factor application is a potential therapeutic strategy to improve diabetic foot ulcer healing and prevent amputation.
    Çetinkaya ÖA; Çelik SU; Erzincan MB; Hazır B; Uncu H
    Turk J Surg; 2020 Mar; 36(1):15-22. PubMed ID: 32637871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curative Metatarsal Bone Surgery Combined with Intralesional Administration of Recombinant Human Epidermal Growth Factor in Diabetic Neuropathic Ulceration of the Forefoot: A Prospective, Open, Uncontrolled, Nonrandomized, Observational Study.
    Garcia Herrera AL; Febles Sanabria RJ; Acosta Cabadilla LLÁ; Moliner Cartaya M
    Curr Ther Res Clin Exp; 2017; 85():2-7. PubMed ID: 29158852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGF, a veteran of wound healing: highlights on its mode of action, clinical applications with focus on wound treatment, and recent drug delivery strategies.
    Shakhakarmi K; Seo JE; Lamichhane S; Thapa C; Lee S
    Arch Pharm Res; 2023 Apr; 46(4):299-322. PubMed ID: 36928481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.